---
document_datetime: 2025-11-14 15:48:32
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/comirnaty-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: comirnaty-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.3128714
conversion_datetime: 2025-12-24 05:22:24.222998
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## COMIRNATY

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 04/11/2025                          |                                             | SmPC,                            |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000303772                     | variations. C.I.7 Deletion of: - C.I.7.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.a Deletion of a supplier - Accepted B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.3 Deletion of an immediate packaging container that does not lead to the complete deletion of a strength or pharmaceutical   |            |     | Labelling and PL   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation type II / EMA/VR/0000282346 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/10/2025 | N/A |                    |

<div style=\"page-break-after: always\"></div>

|                                       | Submission of the final report for the non- interventional study C4591038, listed as category 3 study in the RMP. This is a post- authorisation active surveillance study of myocarditis and pericarditis among individuals in Europe receiving Comirnaty.                                                |            |            |                        |                                                                                                                 |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000291737 | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted                                                                                                                                 | 01/09/2025 |            | SmPC, Labelling and PL |                                                                                                                 |
| Variation type II / EMA/VR/0000275515 | B.I.a.6 Changes to the active substance of a vaccine against human coronavirus - B.I.a.6.a Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine - Accepted                        | 24/07/2025 | 25/07/2025 | SmPC, Labelling and PL | Addition of a new strain (Omicron LP.8.1) resulting in six new monovalent presentations (EU/1/20/1528/045-050). |
| Variation type II / EMA/VR/0000262269 | This was an application for a group of variations. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be | 10/07/2025 | N/A        |                        |                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | submitted by the MAH where significant assessment by the competent authority is required* - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Refused C.I.11.b: Submission of an updated RMP version 15.0 in order to revise key objectives, design and study population of study C4591048 according to protocol amendment 6. In addition, minor administrative changes were implemented in   |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000274567 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        |                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000268620 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted | 20/05/2025 | N/A        |                        |                                                                                                                                                                                                                                                                                                      |
| Variation type II / EMA/VR/0000255124 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/05/2025 | 25/07/2025 | SmPC, Labelling and PL | The SmPC (sections 6.3, 6.4, 6.6 & 8) has been updated to include the new 30 µg multi dose vial (MDV) presentations, for Omicron JN.1 and KP.2 variants (EU/1/20/1528/043-044), intended for refrigerated-only storage conditions at 2-8°C, with 12-month shelf life. The Labelling and PL have been |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.f) Stability - B.II.f.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                  | updated accordingly.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------|
| Variation type IB / EMA/VR/0000265207 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.3 Change in name of the active substance or of an excipient - Accepted B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished | 29/04/2025 | 25/07/2025 | SmPC, Annex II, Labelling and PL |                        |

<div style=\"page-break-after: always\"></div>

| control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  B.I.a.2 Changes in the manufacturing   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | process of the active substance - B.I.a.2.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| Variation type IB / EMA/VR/0000248834 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e | 12/03/2025 | 25/07/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

|                                       | Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000247144 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted | 03/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted   |            |            |             |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IB / EMA/VR/0000246825 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (IB) - To update the product information by streamlining and combining the SmPC according to 'primary pharmaceutical form' for each international non-proprietary name (INN) of the presentations of the Comirnaty product family. In addition, the applicant took the opportunity to implement minor editorial changes in sections 4.6, 4.8 and 5.1 of the                                                                                                                                     | 28/02/2025 | 25/07/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | SmPC and sections 4 and 6 of the PIL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IB / EMA/VR/0000248036 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/02/2025 | N/A        |             |
| Variation type II / EMA/VR/0000239564 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.9 of the SmPC in order to rephrase the information on overdose based on 3 overdose medication errors that were observed in the interventional study C4591007; this was a phase 1, open-label dose-finding study to evaluate safety, tolerability, and immunogenicity and phase 2/3 placebo controlled, observer blinded safety, tolerability, and immunogenicity study of a SARS-CoV-2 RNA vaccine candidate against COVID-19 in healthy children and young adults. In addition, the MAH took the opportunity to implement editorial changes in the product information. | 06/02/2025 | 25/07/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000237985   | 30/01/2025   | 25/07/2025   | SmPC and PL   | The MAH submitted the final results from studies C5481001 sub-study A and B7471026. Study C5481001 sub-study A evaluated coadministration of bivalent Comirnaty Original/Omicron BA.4-5 and an unadjuvanted recombinant prefusion-F-protein respiratory syncytial virus (RSV)-vaccine, with or without a high dose influenza vaccine. This study was designed to evaluate non-inferiority of immune responses after co-administration compared to single vaccinations. Non-inferiority were met for all antigens, i.e. the lower bound of the 2-sided 97.5% CI for geometric mean ratio (GMR) was >0.5. Study B7471026 described coadministration of Comirnaty with 20-valent pneumococcal conjugate vaccine. This study was of descriptive nature and the updates to the product information were based on post-hoc analysis on immunogenicity. The MAH showed that if a 2 fold non-inferiority margin (lower bounds of the 2-sided 95% CIs for the model-based opsonophagocytic activity (OPA) GMRs >0.5) was applied to the results, OPA activity GMRs would have met non-inferiority criteria for all 20 serotypes. No additional safety concerns were identified in both studies. For more information, please refer to the Summary of Product Characteristics.   |
|-----------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | SmPC in order to update information regarding concomitant administration of Comirnaty with conjugate pneumococcal vaccine based on final results from interventional study B7471026; this is a Phase 3, randomised, double-blind study aimed to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when co-administered with a booster dose of Comirnaty in adults 65 years of age and older. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000231382 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or                                            | 16/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                                                                                                                                                                                 |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000233365 | This was an application for a group of variations. B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used)) - B.II.e.6.b Change that does not affect the product information - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ | 16/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | pharmaceutical forms manufactured by complex manufacturing processes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000231586 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted A grouped application consisting of: C.I.11.b: Submission of an updated RMP version 13.1 in order to include Protocol amendment no. 5 where the study design and objectives were revised for an interventional study C4591048, a master phase 1/2/3 protocol to investigate the safety, tolerability, and immunogenicity of | 16/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | candidate(s) in healthy children, listed as a category 3 study in the RMP. C.I.13: Submission of the final report from study C4591044 listed as a category 3 study in the RMP. This is an interventional randomized, active controlled, Phase 2/3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b RNA- Based Vaccine Candidates as A Booster Dose In COVID-19 Vaccine-Experienced Healthy Individuals. The RMP version 13.1 has also been submitted.           |            |            |                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IB / EMA/VR/0000236983 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted C.I.7 Deletion of: - C.I.7.z Other variation - Accepted C.I.7 Deletion of: - C.I.7.z Other variation - Accepted | 12/12/2024 | 25/07/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| Original dispersion for injection and concentrate for dispersion for injection presentations (Tozinameran: EU/1/20/1528/002-005, 010 and 013). C.I.7.z (IB) - To delete all bivalent Comirnaty Original/Omicron BA.4-5 dispersion for injection and concentrate for dispersion for injection presentations (Tozinameran/Famtozinameran: EU/1/20/1528/008-009, 011-012 and 014- 017). A.7 (IA) - To delete the following finished product manufacturing sites: - Baxter as site responsible for fill and finish, secondary packaging and testing of the finished product. This change is applicable for presentations EU/1/20/1528/008-009. - Sanofi Sanofi-Aventis Deutschland GmbH, Brueningstrasse 50, 65926 Frankfurt am Main, Germany as site responsible for fill and finish, secondary packaging and testing of the finished product. This change is applicable for presentations EU/1/20/1528/002-003, EU/1/20/1528/008- 009. - Allergopharma GmbH & Co. KG, Hermann-Körner-Straße 52, 21465 Reinbek, Germany as LNP Production and bulk drug product formulation site of the finished product. This change is applicable for presentations EU/1/20/1528/002-003, EU/1/20/1528/008-009. - Patheon Italia S.p.A., Viale G.B. Stucchi 110, 20900 Monza   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | finish, secondary packaging and testing of the finished product. This change is applicable for presentations EU/1/20/1528/002-003, EU/1/20/1528/008- 009. Additionally, the Applicant is taking the opportunity to include the following editorial updates: - To remove section 3.2.P.3.4 Control of Critical Steps and Intermediates - In-Process Monitoring and Controls - LNP Production and Bulk Drug Product Formulation - Bivalent [Original and Omicron (B.1.1.529)] - Puurs. - To reinstate a copy of section 3.2.P.2 Pharmaceutical Development - Introduction - [Omicron (XBB.1.5) Variant]. - Updated stability results for Tris/Sucrose Original and Bivalent [Original and Omicron (BA.4/BA.5) Variant]. - Minor editorial revisions throughout the PI.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000234231 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate /                                                                                                                                                                                                                                                                                                                                         | 25/11/2024 | N/A |

<div style=\"page-break-after: always\"></div>

| reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the   |            |            |             |                                                           |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------|
| Variation type II / EMA/VR/0000224683 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/11/2024 | 25/07/2025 | SmPC and PL | Please refer to Scientific Discussion 'EMA/VR/0000224683' |

<div style=\"page-break-after: always\"></div>

| C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application comprised of 3 Type II Variations as follows: C.I.4: Update of sections 4.6, 4.8 and 5.1 of the SmPC in order to update pregnancy related information based on final results from interventional study C4591015, listed as a category 3 study in the RMP. Study C4591015 is a phase 2/3, placebo controlled, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of a SARS-CoV-2 RNA vaccine candidate (BNT162b2) against COVID-19 in healthy pregnant women 18 years of age and older. The Package Leaflet is updated accordingly. C.I.4: Update of sections 4.4, 4.8 and 5.1 of the SmPC in   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | immunocompromised individuals based on final results from interventional study C4591024, listed as a category 3 study in the RMP. Study C4591024 is a phase 2b, open-label study to evaluate the safety, tolerability, and immunogenicity of vaccine candidate BNT162b2 in immunocompromised participants ≥2 years of age. The Package Leaflet is updated accordingly. C.I.13: Submission of the C4591030 (secondary BNT162b2 immunogenicity endpoint analysis) supplementary (post-final) clinical study report. This is a phase 3, randomized, observer-blind trial to evaluate the safety and immunogenicity of BNT162b2 when co- administered with seasonal inactivated influenza vaccine (SIIV) in adults 18 through 64 years of age. In addition, the MAH took the opportunity to introduce minor editorial   |            |            |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| Variation type II / EMA/VR/0000228506 | This was an application for a group of variations. B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/11/2024 | 25/07/2025 |

<div style=\"page-break-after: always\"></div>

| B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.b Downscaling down to 10-fold - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.b Downscaling down to 10-fold - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000232912   | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted                                                                                                                                                                                                                                                                                      | 04/11/2024   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000232784   | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.d Other changes to a test procedure (including replacement or addition) - Accepted | 31/10/2024   | N/A   |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000230516   | 21/10/2024   | N/A   |
|-----------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                                       | substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an   |            |            |                        |                                                                                                                 |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000225514 | B.I.a.6 Changes to the active substance of a vaccine against human coronavirus - B.I.a.6.a Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine - Accepted                                                                                                                                                                                                                                                                                                                        | 19/09/2024 | 26/09/2024 | SmPC, Labelling and PL | Addition of a new strain (Comirnaty KP.2, SARS- CoV-2 KP.2 mRNA) resulting in six new monovalent presentations. |
| Variation type IB / EMA/VR/0000224164 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/08/2024 | N/A        |                        |                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000223630 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted | 14/08/2024 | N/A |

<div style=\"page-break-after: always\"></div>

|                            | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted   |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000257861 | - -                                                                                                                              |